United Laboratories International Unit's Antibiotic Drug Passes Chinese Regulator's Consistency Evaluation
MT Newswires Live2024-10-28
United Laboratories International (HKG:3933) said Oct. 25 that ceftazidime for injection submitted by unit Zhuhai United Laboratories, Zhongshan Branch, has passed China's National Medical Products Administration's consistency evaluation of quality and efficacy for generic drugs, a same-day bourse filing said.
The drug is a third-generation cephalosporin antibiotic and is used to treat infections caused by susceptible microorganisms, including severe systemic, lower respiratory tract, and urinary tract infections among others.
Price (HKD): $11.10, Change: $-0.100, Percent Change: -0.89%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
